Indication
Respiratory cystic fibrosis with Pseudomonas aeruginosa colonization
Respiratory cystic fibrosis with *Pseudomonas aeruginosa* colonization refers to the persistent or recurrent presence of the opportunistic gram-negative bacterium *Pseudomonas aeruginosa* within the tracheobronchial tree of patients with cystic fibrosis. Read more about Respiratory cystic fibrosis with Pseudomonas aeruginosa colonization
31 drugs 23 manufacturers
Drugs that treat it
Common Respiratory cystic fibrosis with Pseudomonas aeruginosa colonization therapies.
TOBI PODHALER (tobramycin)
TOBI (tobramycin in 0.225 % sodium chloride)
TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)
TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)
TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)
TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)
TOBRAMYCIN
TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRespiratory cystic fibrosis with *Pseudomonas aeruginosa* colonization refers to the persistent or recurrent presence of the opportunistic gram-negative bacterium *Pseudomonas aeruginosa* within the tracheobronchial tree of patients with cystic fibrosis.
In this population, defective cystic fibrosis transmembrane conductance regulator (CFTR) function leads to dehydrated, hyperviscous airway secretions and impaired mucociliary clearance, creating an ideal niche for bacterial adherence and proliferation.
Colonization often transitions from early, intermittent non-mucoid strains to chronic infection characterized by biofilm-forming, mucoid phenotypes that resist host defenses.
This clinical state triggers sustained airway inflammation, accelerated pulmonary architecture damage, worsening airflow obstruction, and an elevated risk of acute pulmonary exacerbations.
- nih.gov
Respiratory cystic fibrosis with *Pseudomonas aeruginosa* colonization refers to the persistent or recurrent presence of the opportunistic gram-negative bacterium *Pseudomonas aeruginosa* within the tracheobronchial tree of patients with cystic fibrosis Colonization often transitions from early, intermittent non-mucoid strains to chronic infection characterized by biofilm-forming, mucoid phenotypes that resist host defenses
- cfdb.eu
Respiratory cystic fibrosis with *Pseudomonas aeruginosa* colonization refers to the persistent or recurrent presence of the opportunistic gram-negative bacterium *Pseudomonas aeruginosa* within the tracheobronchial tree of patients with cystic fibrosis Colonization often transitions from early, intermittent non-mucoid strains to chronic infection characterized by biofilm-forming, mucoid phenotypes that resist host defenses This clinical state triggers sustained airway inflammation, accelerated ...
- nih.gov
In this population, defective cystic fibrosis transmembrane conductance regulator (CFTR) function leads to dehydrated, hyperviscous airway secretions and impaired mucociliary clearance, creating an ideal niche for bacterial adherence and proliferation
- frontiersin.org
In this population, defective cystic fibrosis transmembrane conductance regulator (CFTR) function leads to dehydrated, hyperviscous airway secretions and impaired mucociliary clearance, creating an ideal niche for bacterial adherence and proliferation
- nih.gov
This clinical state triggers sustained airway inflammation, accelerated pulmonary architecture damage, worsening airflow obstruction, and an elevated risk of acute pulmonary exacerbations
- cysticfibrosisnewstoday.com
This clinical state triggers sustained airway inflammation, accelerated pulmonary architecture damage, worsening airflow obstruction, and an elevated risk of acute pulmonary exacerbations
Personalize your experience
Follow Respiratory cystic fibrosis with Pseudomonas aeruginosa colonization and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.